Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Towa Expands Internationally With Esteve’s Pensa

All-Cash €320m Deal Offers Access To Europe And US

Executive Summary

Japan’s Towa has struck a deal to acquire the Pensa Investments generics division of Spain’s Esteve in an all-cash transaction worth €320m. The acquisition gives Towa access to the Spanish market as well as subsidiaries in Europe and the US.

You may also be interested in...



Towa Completes Deal For Pensa

Japan’s Towa has completed its €329m deal for the Pensa Investments generics business of Spain’s Esteve.

Deal Watch: Pfizer Licenses Skin-Targeted JAK Inhibitor Portfolio From Theravance

Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.

Towa to proactively expand

Entering new markets, including the US, through partnerships forms a key part of Towa Pharmaceutical’s ‘Proactive’ medium-term business plan. Editor Aidan Fry examines the Japanese generics specialist’s growth strategy.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL065251

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel